公开(公告)号：US20160113922A1

公开(公告)日：2016-04-28

申请号：US14985417

申请日：2015-12-31

Applicant: Macau University of Science and Technology

Inventor： Kam Wai WONG ,  Yuen Kwan LAW ,  Liang LIU ,  Jingrong WANG

IPC: A61K31/4745 ,  A61K31/4725

CPC classification number: A61K31/4745 ,  A61K31/4725 ,  A61K31/4748

Abstract: The present invention discloses a method of treating cancer comprising administering an effective amount of an alkaloid, in which the alkaloid is liensinine, isoliensinine, dauricine, cepharanthine, hernandezine or thalidezine and isolated from the traditional Chinese medicinal herbs. The use of the alkaloid in treating neurodegenerative disorder is also disclosed.

公开(公告)号：US20160106732A1

公开(公告)日：2016-04-21

申请号：US14985412

申请日：2015-12-31

Applicant: Macau University of Science and Technology

Inventor： Kam Wai WONG ,  Yuen Kwan LAW ,  Liang LIU ,  Jingrong WANG

IPC: A61K31/4748 ,  A61K31/4725

CPC classification number: A61K31/4745 ,  A61K31/4725 ,  A61K31/4748

Abstract: The present invention discloses a method of treating cancer comprising administering an effective amount of an alkaloid, in which the alkaloid is liensinine, isoliensinine, dauricine, cepharanthine, hernandezine or thalidezine and isolated from the traditional Chinese medicinal herbs. The use of the alkaloid in treating neurodegenerative disorder is also disclosed.

公开(公告)号：US20150050363A1

公开(公告)日：2015-02-19

申请号：US14231671

申请日：2014-03-31

Applicant: Macau University of Science and Technology

Inventor： Yuen Kwan LAW ,  An Guo WU ,  Kam Wai WONG ,  Liang LIU

IPC: A61K36/69

CPC classification number: A61K36/69 ,  A61K31/704

Abstract: Use and application of Onjisaponin B derived and isolated from Radix Polygalae as novel autophagy enhancer are provided. A method of preventing, treating and/or delaying the onset of neurodegenerative diseases comprising administering an effective amount of Onjisaponin B is also provided.

Abstract translation: 本发明提供了从根部提取和分离的Onjisaponin B作为新的自噬增强剂的应用和应用。 还提供了预防，治疗和/或延缓神经变性疾病发作的方法，包括给予有效量的Onjisaponin B.

公开(公告)号：US20140371254A1

公开(公告)日：2014-12-18

申请号：US14285651

申请日：2014-05-23

Applicant: Macau University of Science and Technology

Inventor： Lai Han LEUNG ,  Xing Xing FAN ,  Liang LIU

IPC: A61K31/4741

CPC classification number: A61K31/4741

Abstract: The present invention discloses a method of preventing and treating Gefitinib-resistant non-small-cell lung cancer, comprising administering an effective amount of an alkaloid. A pharmaceutical composition comprising an alkaloid admixed with a pharmaceutical carrier for treating Gefitinib-resistant non-small-cell lung cancer is also disclosed therein.

Abstract translation: 本发明公开了一种预防和治疗吉非替尼抗性非小细胞肺癌的方法，包括给予有效量的生物碱。 还公开了包含与用于治疗吉非替尼非小细胞肺癌的药物载体混合的生物碱的药物组合物。

公开(公告)号：US20190060273A1

公开(公告)日：2019-02-28

申请号：US15682564

申请日：2017-08-22

Applicant: Macau University of Science and Technology

Inventor： Ying XIE ,  Liang LIU ,  Hua ZHOU

IPC: A61K31/357 ,  A61K31/352 ,  A61K9/00 ,  A61K9/20

Abstract: One example embodiment relates to a method of increasing bioavailability of silybin in a person. The method includes providing silybin and a flavonoid to the person, wherein the flavonoid is tangeretin or baicalein. Another example embodiment relates to a method of treating chronic liver disease in a person by administering silybin and a flavonoid to the person to treat the chronic liver disease.

公开(公告)号：US20170056390A1

公开(公告)日：2017-03-02

申请号：US14925962

申请日：2015-10-28

Applicant: Macau University of Science and Technology

Inventor： Kam Wai WONG ,  Yuen Kwan LAW ,  Liang LIU

IPC: A61K31/4745

CPC classification number: A61K31/4745

Abstract: The present invention discloses a method of treating cancer and/or multidrug-resistant cancer, comprising administering an effective amount of hernandezine or thalidezine. A pharmaceutical composition comprising hernandezine or thalidezine admixed with a pharmaceutical carrier for treating cancers and/or multidrug-resistant cancer is also disclosed.

Abstract translation: 本发明公开了一种治疗癌症和/或多药耐药性癌症的方法，其包括施用有效量的涕灭威或沙利度胺。 还公开了包含与用于治疗癌症和/或多药耐药性癌症的药物载体混合的栀子苷或沙利度胺的药物组合物。

公开(公告)号：US20160037757A1

公开(公告)日：2016-02-11

申请号：US14620141

申请日：2015-02-11

Applicant: Macau University of Science and Technology

Inventor： Liang LIU ,  Ting LI ,  Kam Wai WONG ,  Zhihong JIANG ,  Hua ZHOU

IPC: A01K67/027 ,  A61K49/00

CPC classification number: A01K67/0278 ,  A01K2207/12 ,  A01K2227/105 ,  A01K2267/01 ,  A01K2267/0368 ,  A61K49/0008 ,  G01N33/573 ,  G01N33/574 ,  G01N2333/91215 ,  G01N2800/102 ,  G01N2800/44

Abstract: The present invention provides an in vivo platform for identifying and determining therapeutic or prophylactic activity of test compounds in delay-type hypersensitivity (DTH) and other inflammatory or cancerous diseases mediated by activation of IKK-βC46A mutants. The in vivo platform of the present invention is a non-human transgenic mammal, e.g., a mouse model, with a site directed mutagenesis at a cysteine residue replaced by alanine in IKK-β protein kinase. The site directed mutagenesis is introduced by a specially designed targeting vector containing a transversion in exon 3 of the Ikbkb genes encoding the IKK-β. The present invention also provides methods for generating the transgenic mammal and for determining and identifying compounds that can inhibit activation of IKK-βC46A mutants.

Abstract translation: 本发明提供了一种用于鉴定和确定延迟型超敏反应（DTH）和通过IKK-和bgr C46A突变体的活化介导的其它炎性或癌性疾病的测试化合物的治疗或预防活性的体内平台。 本发明的体内平台是非人转基因哺乳动物，例如小鼠模型，在IKK-和bgr中被半胱氨酸残基替换为丙氨酸的位点定向诱变; 蛋白激酶。 通过特异设计的靶向载体引入定点诱变，所述靶向载体在编码IKK-＆bgr的Ikbkb基因的外显子3中含有颠换。 本发明还提供了产生转基因哺乳动物以及用于测定和鉴定可以抑制IKK-Bgr C46A突变体活化的化合物的方法。

公开(公告)号：US20150307508A1

公开(公告)日：2015-10-29

申请号：US14645406

申请日：2015-03-11

Applicant: Macau University of Science and Technology

Inventor： Lai-Han LEUNG ,  Liang LIU ,  Xing-Xing FAN ,  Jian-Lin WU

IPC: C07D491/056

CPC classification number: C07D491/056

Abstract: The present invention discloses a method of treating Gefitinib-resistant non-small-cell lung cancer, comprising administering an effective amount of an alkaloid. A pharmaceutical composition comprising an alkaloid admixed with a pharmaceutical carrier for treating Gefitinib-resistant non-small-cell lung cancer is also disclosed therein.

Abstract translation: 本发明公开了一种治疗吉非替尼的非小细胞肺癌的方法，包括给予有效量的生物碱。 还公开了包含与用于治疗吉非替尼非小细胞肺癌的药物载体混合的生物碱的药物组合物。

公开(公告)号：US20190178885A1

公开(公告)日：2019-06-13

申请号：US16281122

申请日：2019-02-21

Applicant: Macau University of Science and Technology

Inventor： Liang LIU ,  Jing-Rong WANG ,  Weina GAO ,  Leefong YAU ,  Hao HUANG ,  Qiong MENG ,  Tiantian TONG ,  Zhi-Hong JIANG

IPC: G01N33/564 ,  B01L3/00 ,  G01N1/40 ,  G01N30/08 ,  G01N30/60 ,  G01N30/72

Abstract: The present invention discloses a method of determining the presence of autoimmune disease with the use of glycan biomarkers. A method of improving the detection sensitivity of trace glycans from a mixture of glycans and a microfluidic chip therefor are also disclosed.

公开(公告)号：US20180305300A1

公开(公告)日：2018-10-25

申请号：US15495949

申请日：2017-04-24

Applicant: Macau University of Science and Technology

Inventor： Guo-Yuan ZHU ,  Zhi-Hong JIANG ,  Ji YANG ,  Xiao-Jun YAO ,  Xin LIU ,  Jing FU ,  Li-Ping BAI ,  Liang LIU

IPC: C07C237/26 ,  C07C231/24

CPC classification number: A61K31/00 ,  A61P25/28 ,  C07C235/82 ,  C07C2603/97

Abstract: One example embodiment is a lignanamide that includes a benzo-angular triquinane skeleton. The lignanamide is represented by formula (I) and any derivative of the formula (I), in which R is represented by —OH or —OCH3. Another example embodiment relates to a method of treating neurodegenerative disease by administering the lignanamide of the formula (I) to a person in need thereof.